Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- Drug: MHB088C for Injection
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Minghui Pharmaceutical Pty Ltd
- Target Recruit Count
- 48
- Registration Number
- NCT05652855
- Locations
- ๐ฆ๐บ
Pindara Private Hospital, Gold Coast, Queensland, Australia
๐ฆ๐บCabrini Health, Melbourne, Victoria, Australia
๐ฆ๐บSouthern Oncology Clinical Research Unit, Adelaide, South Australia, Australia
Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Minghui Pharmaceutical Pty Ltd
- Target Recruit Count
- 400
- Registration Number
- NCT05642949
- Locations
- ๐ฆ๐บ
Pindara Private Hospital, Gold Coast, Queensland, Australia
๐ฆ๐บSouthern Oncology Clinical Research Unit, Adelaide, South Australia, Australia
๐ฆ๐บCabrini Health, Melbourne, Victoria, Australia
MH004 Topical Cream in Healthy Adult Volunteers and Participants With Atopic Dermatitis or Rheumatoid Arthritis
Phase 1
- Conditions
- Atopic DermatitisRheumatoid Arthritis
- Interventions
- Drug: MH004 Ia(1%)Drug: MH004 Ia(3%)Drug: MH004 Ib-1(1%)Drug: MH004 Ib-2(0.3%)Drug: MH004 Ia(0.3%)Drug: MH004 Ib-1(0.1%)Drug: MH004 Ib-2(1%)Drug: MH004 Ib-2(3%)Drug: MH004 Ia(0.1%)Drug: MH004 Ib-1(0.3%)
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- Minghui Pharmaceutical Pty Ltd
- Target Recruit Count
- 72
- Registration Number
- NCT04815148
ยฉ Copyright 2025. All Rights Reserved by MedPath